DelveInsight's Report Reveals Significant Growth Potential in the Common Warts Market | Companies- Nielsen BioSciences, Veloce BioPharma, Verrica Pharmaceutical, Maruho Co., Ltd, Aclaris Therapeutics, Inc., and Others

DelveInsight, a leading market research and consulting firm, has released a comprehensive market report on the Common Warts Market. The report provides valuable insights into the current market scenario, emerging trends, key players, competitive landscape, and growth prospects in the Common Warts Market.

The Common Warts market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted Common Warts symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Common Warts symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Discover more about therapies set to grab major Common Warts Market Share @ Common Warts Market Size- https://www.delveinsight.com/sample-request/common-warts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Common Warts Market Report
• The Common Warts market size in the 7MM was found to be USD 720.03 million in 2020.
• The increase in market size of Common Warts is a direct consequence of expected approval of emerging therapies and increasing patient population of Common Warts in the 7MM.
• As per DelveInsight estimates, the diagnosed prevalent cases were observed to be same for male and female in the 7MM.
• The leading Common Warts Companies include Nielsen BioSciences, Veloce BioPharma, Verrica Pharmaceutical, Maruho Co., Ltd, Aclaris Therapeutics, Inc., and others
• Promising Common Warts Pipeline Therapies include A-101, Podofilox Gel 0.5%, Condylox Topical Gel 0.5%, CLS006, Vehicle Topical Gel, Imiquimod 5% cream, 2LVERU® or 2LVERU® JUNIOR, 2.5% imiquimod cream, 3.75% imiquimod cream, and others
• CANDIN: Being developed by Nielsen BioSciences, has completed Phase II clinical trials to assess the safety and efficacy in, and the company is currently planning for a pivotal Phase III study with patient enrollment expected to start in the second half of 2023. CANDIN is already approved as a skin test antigen for the assessment of cellular hypersensitivity to Candida albicans. CANDIN shows encouraging phase II results for common and non-common warts among adults. Neilson recently entered into a license agreement with Maruho, granting it exclusive rights to market CANDIN in Japan for the treatment of Verruca vulgaris.
• VP-102, being developed by Verrica Pharmaceutical, is drug-device combination product with a topical cantharidine 0.7% solution that is manufactured according to Current Good Manufacturing Practices, delivered via a single-use applicator for precise topical dosing and targeted administration. Verrica has announced promising top line results from its COVE-1 Phase II open-label trial. Currently, the company is evaluating potential for conducting an additional Phase II trial based on the US FDA feedback for Phase III trial protocol.

To explore more information on the latest breakthroughs in the Common Warts treatment landscape of the report, click here @ Common Warts Market Outlook- https://www.delveinsight.com/sample-request/common-warts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Common Warts Overview
Common warts, also known as verruca vulgaris, are caused by nonmalignant strains of human papillomavirus (HPV). They are typically benign lesions that rarely have malignant transformation. On the skin, they appear as rough, painless papules that can be grey or flesh-colored and are found on different body areas. Other subtypes of HPV that are associated with cervical cancer are not the same strains that cause verruca vulgaris (Pope et al., 2020).

Common Warts Epidemiology Segmentation in the 7MM
• Common Warts Diagnosed Prevalent Cases
• Common Warts Gender-specific Prevalence

Download the report to understand which factors are driving Common Warts Epidemiology Trends @ Common Warts Epidemiological Insights- https://www.delveinsight.com/sample-request/common-warts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Common Warts Treatment Market
The treatment strategies can be organized into three groups: physical or chemical destruction, immune-modulating agents, and antiproliferation agents. Even with treatment, warts tend to recur or spread. The current treatment landscape is governed by following:

Destructive methods aim to destroy or remove the wart itself, not at killing the HP virus. Tissue destruction can be achieved by physical as well as chemical means. Physical methods utilize cold temperatures or mechanical exposure and include cryotherapy, curettage, and surgical excision, and lasers may also be used in this context. Chemical compounds with destructive properties include keratolytic agents, such as salicylic acidorlactic acid, and caustic agents, such as monochloroacetic acid or silver nitrate. Salicylic acid: Salicylic acid is most commonly used medication for warts and is available as over-the counter and prescriptive strength. Prescription-strength wart medications with salicylic acid work by removing layers of awart a little bit at a time. Salicylic is available with other formulations and is usually combined with cryotherapy and laser.
Freezing (cryotherapy): Freezing works by causing a blister to form under and around the wart, then the deadtissue sloughs off within a week or so. This method may also stimulate the immune system to fight viral warts.The procedure often requires to be repeated. The side effects include pain, blistering and discolored skin in the treated area.

Other acids: These include trichloroacetic acid, the process requires to first shave the surface of the wart and then applies the acid with a wooden toothpick. It requires repeat treatments every week. Side effects are burning and stinging.

Common Warts Emerging Drugs

• Candin: Nielsen BioSciences
Results in Phase II research involving common and non-common warts among adults were highly encouraging and are now advancing clinical research into the use of the antigen in common and non-common warts. Though not treated, plantar, periungual, flat, facial, and genital warts were evaluated in the Phase II subjects (Nielsen Biosciences, 2021).
Treatment of common warts with intralesional candida antigen appears safe and effective. Further studies are warranted to confirm the dosing scheme and demonstrate safety and effectiveness for FDA licensure (Smith & Johnson, 2019).

• VP-102: Verrica Pharmaceutical
The pharmacodynamic action of the active ingredient in VP-102 (cantharidin) is a vesicant. VP-102 is currently under the US FDA review and could potentially be the first product approved by the FDA to treat mollusum contagiosum (mollusum) - a common, highly contagious skin disease that affects an estimated 6 million people in the United States, primarily children. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name, YCANTH. Verrica has announced positive top-line results from its COVE-1 Phase II open-label clinical study of VP-102 to treat common warts (Verrica Pharmaceuticals., 2021).

Common Warts Market Dynamics
The dynamics of the Common Warts market are anticipated to change in the coming years due to the increasing awareness and improved diagnosis of the disease. Key players, such as Nielsen BioSciences, Maruho, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharmaceutical, and others, are developing drugs for common warts.

To know more about Common Warts Therapies options, visit @ Common Warts Therapeutics Market- https://www.delveinsight.com/sample-request/common-warts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Common Warts Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Common Warts Companies- Nielsen BioSciences, Veloce BioPharma, Verrica Pharmaceutical, Maruho Co., Ltd, Aclaris Therapeutics Inc, and others
• Common Warts Pipeline Therapies- A-101, Podofilox Gel 0.5%, Condylox Topical Gel 0.5%, CLS006, Vehicle Topical Gel, Imiquimod 5% cream, 2LVERU® or 2LVERU® JUNIOR, 2.5% imiquimod cream, 3.75% imiquimod cream, and others
• Common Warts Market Dynamics: Common Warts Market Drivers and Barriers

Discover more about Common Warts Drugs in development @ Common Warts Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/common-warts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Common Warts Market Overview at a Glance
4. Executive Summary of Common Warts
5. Disease Background and Overview
6. Management and Treatment
7. Epidemiology and Patient Population
8. Patient Journey 1
9. Patient Journey 2
10. Emerging Therapies
11. Current Marketed Therapies: Generics
12. Other Topical Agents
13. Common Warts: 7 Major Market Analysis
14. Market Outlook
15. KOL Views
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Learn more about the Common Warts Pipeline Therapies in clinical trials @ Common Warts SWOT Analysis, Unmet Needs, Reimbursement, and Patient Journey- https://www.delveinsight.com/sample-request/common-warts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.